| 前收盘价格 | 7.41 |
| 收盘价格 | 7.36 |
| 成交量 | 8,181,727 |
| 平均成交量 (3个月) | 1,013,729 |
| 市值 | 377,533,664 |
| 价格/销量 (P/S) | 4.20 |
| 股市价格/股市净资产 (P/B) | 1.22 |
| 52周波幅 | |
| 利润日期 | 25 Feb 2025 - 3 Mar 2025 |
| 营业毛利率 | -283.19% |
| 营业利益率 (TTM) | -256.55% |
| 稀释每股收益 (EPS TTM) | -5.01 |
| 季度收入增长率 (YOY) | -16.30% |
| 总债务/股东权益 (D/E MRQ) | 48.37% |
| 流动比率 (MRQ) | 3.05 |
| 营业现金流 (OCF TTM) | -182.26 M |
| 杠杆自由现金流 (LFCF TTM) | -95.26 M |
| 资产报酬率 (ROA TTM) | -26.03% |
| 股东权益报酬率 (ROE TTM) | -71.87% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | REGENXBIO Inc. | 看跌 | 看涨 |
AIStockmoo 评分
0.9
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.88 |
|
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 7.39% |
| 机构持股比例 | 92.34% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Integral Health Asset Management, Llc | 30 Sep 2024 | 1,275,000 |
| Aquilo Capital Management, Llc | 30 Sep 2024 | 930,708 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 52.00 (Chardan Capital, 582.42%) | 购买 |
| 中 | 35.00 (359.32%) | |
| 低 | 18.00 (Raymond James, 136.22%) | 购买 |
| 平均值 | 32.60 (327.82%) | |
| 总计 | 5 购买 | |
| 平均价格@调整类型 | 9.41 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| RBC Capital | 11 Dec 2024 | 35.00 (359.32%) | 购买 | 9.30 |
| HC Wainwright & Co. | 21 Nov 2024 | 36.00 (372.44%) | 购买 | 9.18 |
| 07 Nov 2024 | 40.00 (424.93%) | 购买 | 11.19 | |
| Chardan Capital | 20 Nov 2024 | 52.00 (582.41%) | 购买 | 9.63 |
| 22 Oct 2024 | 52.00 (582.41%) | 购买 | 9.59 | |
| Morgan Stanley | 15 Nov 2024 | 22.00 (188.71%) | 购买 | 9.63 |
| Raymond James | 10 Oct 2024 | 18.00 (136.22%) | 购买 | 9.29 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合